Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RU-486 Under Attack: Abortion Groups Sue States To Restrict Off-Label Use

Executive Summary

Eight years after FDA approved RU-486, two states have engaged in a legal battle to restrict patient access by attempting to prevent physicians from prescribing the abortion pill for off-label uses

You may also be interested in...



States Take Unusual Actions To Control On-Label Drug Supply Amidst COVID-19 Shortages

Sixteen US states have issued executive orders or other mandatory directives to preserve hydroxychloroquine and chloroquine for non-COVID-19 patients, while 26 states have issued similar voluntary guidance. The federal government is reserving some of the strategic national stockpile supply of the drugs for non-COVID-19, as private players in the supply chain also join in the efforts to balance on-label use with COVID-related demand. 

Senators Pressure US FDA To Issue New Guidance On Social Media Drug Promotion

Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.

Data Monitoring Committees Can Support Certain Adaptive Design Trials, US FDA Says

Draft guidance describes evolution of DMCs and their responsibilities for monitoring trial conduct, internal analyses and external data.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel